Navigation Links
Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
Date:5/14/2013

SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products. For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis' licensees include four of the top 10 largest pharmaceutical companies and two of the top 10 largest generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than fifty issued and pending drug formulation patents covering peptide, protein, and small-molecule drugs.

About Aegis Therapeutics 
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug
'/>"/>

SOURCE Aegis Therapeutics LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
2. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
3. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
4. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
5. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
6. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
7. Combat Medical Systems Awarded $86 Million DOD Contract
8. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
9. CCS Medical Awarded Medicare Contract
10. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
11. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Conn. , Aug. 27, 2014  UBM Medica ... a leading online community for medical imaging professionals, presents ... Association for Medical Imaging Management,s 2014 Annual Meeting . ... conference coverage: , 11 Principles of ... can lead to greater profitability. , Why ...
(Date:8/27/2014)... 2014 Ambit Biosciences (Nasdaq: AMBI ), a ... unmet needs in oncology, autoimmune and inflammatory disease, today announced ... to be held at The New York Palace Hotel in ... 2014. Alan Fuhrman , Ambit,s CFO, will ... candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September 3, ...
(Date:8/27/2014)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... scheduled to make an investor presentation at the Robert W. ... on Wednesday, September 3, in New York City.  ... be available in the Investors section of the IRIDEX website ... IRIDEX Corporation was founded in 1989 and is a ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... December 13, 2011 -- Breadth of ... Pieris AG presented novel preclinical in ... its PRS-080 Anticalin hepcidin antagonist in an oral presentation ... company announced today.  In a presentation entitled "Discovery and ...
... 13, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: ... Ltd. announced that final results from the phase II ... or refractory acute myeloid leukemia (AML) were presented by ... Anderson Cancer Center during the Acute Myeloid Leukemia - ...
Cached Medicine Technology:Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 2Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... especially when your infant looks at you and babbles. ... by listening and responding, they let their infants know ... sounds and using language more quickly. , That,s according ... and Indiana University that found how parents respond to ... communicate and use vocalizations. , The findings challenge the ...
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... 27, 2014 The American Brain ... of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery ... the ABTA is seeding the field with talented, bright ... understanding of the causes, effects, diagnosis and treatment of ... scientific committee based on the potential to advance the ...
(Date:8/27/2014)... While many scientists are trying to prevent the ... autophagy, researchers at Virginia Commonwealth University Massey Cancer ... that causes the process to culminate in cell ... targets the p62 protein, which is often referred ... role in disposing unwanted cellular proteins during autophagy. ...
Breaking Medicine News(10 mins):Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Parents, listen next time your baby babbles 2Health News:Parents, listen next time your baby babbles 3Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2
... already known to predict heart disease may also indicate ... a new Johns Hopkins study. ,C-reactive protein, or ... of CRP have been linked to higher risks of ... and diabetes. Researshers hypothesized that inflammation could play a ...
... legs syndrome is an irritating feeling of uneasiness, tiredness and ... can be painful // and often worsen at night. ... called restless legs syndrome. Studies on restless legs syndrome are ... to look at the prevalence and factors related to restless ...
... source of radiation exposure to the general population. Although ... also believed exposure during the test is responsible for ... to calculate the risk of cancer from exposure to ... and Cancer Research in the United Kingdom conducted the ...
... blood may predict the risk of heart attack or death ... new study. ,Researchers conducted a study to determine whether ... for death or non-fatal heart attack in patients with acute ... factor family and it acts as an instigator of hardening ...
... cancer accounts for the largest number of new cancer ... an international study found the survival rate of non-small-cell ... adjuvant chemotherapy. Cisplatin is an anti-neoplastic medication that interferes ... growth and spread in the body. ,As ...
... percent of diabetics take the proper preventative measures ... Researchers stressed continued negligence by diabetics increases their ... coronary heart disease, stroke, and lower extremity amputations. ... years or older, who had been diagnosed with ...
Cached Medicine News:Health News:Blood Marker Found To Predict Colon Cancer 2
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: